Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Cadherin-11 is expressed in invasive breast cancer cell lines.
- M. Pishvaian, C. Feltes, P. Thompson, M. Bussemakers, J. Schalken, S. Byers
- Biology, Medicine
- Cancer research
- 15 February 1999
Results suggest that cadherin-11 expression may be well correlated with the invasive phenotype in cancer cells and may serve as a molecular marker for the more aggressive, invasive subset of tumors. Expand
Current management of inflammatory bowel disease and colorectal cancer.
- Mark C. Mattar, D. Lough, M. Pishvaian, A. Charabaty
- Gastrointestinal cancer research : GCR
- 1 March 2011
A comprehensive review of the relationship between inflammatory bowel disease and colorectal cancer is presented and major themes covered include risk factors for IBD-CRC, molecular pathobiology of progression from dysplasia to cancer, endoscopic surveillance and new methods for early detection of Dysplasia, approaches to prevention of IBD, and current recommendations and controversies regarding the treatment of dys plasia. Expand
Cross-regulation of β-catenin–LEF/TCF and retinoid signaling pathways
The data suggest that direct regulation of β-catenin–LEF/TCF signaling is one mechanism whereby RA influences development, cell differentiation and cancer. Expand
Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types.
- Arielle L. Heeke, M. Pishvaian, +6 authors C. Isaacs
- Biology, Medicine
- JCO precision oncology
- 23 July 2018
HR-DDR mutations were seen in 17.4% of tumors across 21 cancer lineages, providing a path to explore the role of HRD-directed therapies, including poly-ADP ribose polymerase inhibitors, DNA-damaging chemotherapies, and newer agents such as ATR inhibitors. Expand
Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety
SBRT with concurrent full dose gemcitabine is safe when administered to patients with LAPC and there is no delay in administration of radiation or chemotherapy, and radiation is completed with minimal toxicity. Expand
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
A kinome-wide siRNA screen was used to identify kinases that, when downregulated, yield sensitivity to the ribociclib inhibitor, and highlighted a role for the PI3K-PDK1 signaling pathway in mediating acquired resistance to CDK4/6 inhibitors. Expand
Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation.
It is shown that TGF-beta signaling and Smad adaptor ELF suppress human hepatocarcinogenesis, potentially through cyclin D1 deregulation. Expand
A phase 1 study of efatutazone, an oral peroxisome proliferator‐activated receptor gamma agonist, administered to patients with advanced malignancies
A phase 1 study was conducted to determine the recommended phase 2 dose, safety, tolerability, and pharmacokinetics of efatutazone. Expand
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
- P. Ott, Y. Bang, +11 authors J. Soria
- Journal of clinical oncology : official journal…
- 10 May 2017
Pembrolizumab demonstrated a favorable safety profile and durable antitumor activity in a subgroup of patients with heavily pretreated advanced PD-L1-positive endometrial cancer. Expand
Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).
It is hypothesized that the combination of atezolizumab (atezo; anti–PD-L1) + bev results in a greater clinical benefit due to the additional immunomodulatory effects of bev, which create a more favorable tumor microenvironment that potentiates the efficacy ofatezo. Expand